Cloud-Clone touts ELISA kits for high-sensitivity molecular research

Cloud-Clone Corp. is promoting ready-to-use ELISA kits aimed at preclinical and pharmaceutical research, with claims of pg/mL sensitivity, broad species coverage and support for multiple assay formats. The company says the kits are designed to reduce manual steps and improve consistency across labs worldwide.

Why it matters: - Cloud-Clone is targeting researchers who need fast, quantitative protein, antibody and small-molecule testing in oncology, immunology, endocrinology, drug development and food safety. - The company says the kits are built to reduce preparation errors, improve reproducibility and support work with difficult low-abundance targets. - Broad cross-species coverage and ready-to-use design can lower friction for labs running animal-model studies or high-throughput screening.

What happened: - Cloud-Clone Corp. announced ELISA kits it describes as complete assay systems for global scientific research. - The kits are designed for immediate use without additional matching reagents. - The company says the product line spans thousands of targets across dozens of species, including human, mouse, rat, bovine, porcine and rabbit. - The announcement was dated Aug. 19, 2026, from Houston.

The details: - Each kit includes a pre-coated 96-well detachable microplate with capture antibodies or antigens already immobilized. - The kits include detection antibodies, enzyme conjugates, serial calibrator standards, TMB substrate, stop solution, wash buffer, sealing films and manuals. - Cloud-Clone says the full package works with serum, plasma, cell culture supernatant, tissue homogenate and saliva, among other matrices. - Sandwich ELISA kits are positioned for larger targets such as cytokines, tumor biomarkers and immunoglobulins. - The company says sandwich assays can be completed in about 3 hours and deliver pg/mL-level sensitivity, with intra-assay CV below 10% and inter-assay CV below 15%. - Competitive ELISA kits are aimed at small molecules such as hormones, neurotransmitters and drug residues. - Indirect ELISA kits are designed for antibody detection and serology testing, including HIV and viral antibodies. - Direct ELISA kits are described as a 2-hour option for quick antigen screening and preliminary antibody screening. - Cloud-Clone says the kits achieve pg/mL-range detection, including a BDNF kit with sensitivity lower than 0.118 ng/mL. - The company says recovery rates for complex samples run between 87% and 105%. - Manufacturing follows ISO9001 and ISO13485 quality management standards, according to the company. - Cloud-Clone says each batch is verified for sensitivity, specificity, precision and long-term stability. - The company says target activity attenuation stays under 5% through shelf life and standard curves reach R² greater than 0.99. - Cloud-Clone says more than 40,000 peer-reviewed papers have cited its ELISA kits. - The company also lists social media accounts on LinkedIn, Instagram, TikTok and X.

Between the lines: - The release is structured as a broad product-market pitch, but the technical details are doing most of the work. - Claims around sensitivity, specificity and citation count are meant to position Cloud-Clone against generic ELISA suppliers and signal publication-grade credibility. - The emphasis on ready-to-use formats suggests the company is selling convenience as much as assay performance.

What's next: - Cloud-Clone says it will continue updating immunoassay technology and release new kits for emerging research needs. - The company is likely aiming to expand adoption in preclinical and pharmaceutical workflows where assay consistency and low-abundance detection matter most.